aHUS Trials Watch 6

As aHUS Awareness Day approaches it is timely to be aware of developments in the next version of eculizumab , the version now known as ALXN 1210.

There are 7 trials taking place , 5 for PNH patients and 2 for aHUS patients.

The two trials for aHUS patients are split between adults and children. The  trials will take another 2 years to complete.

The adult trials are about both the amount of the drug which will be needed according to the weight of the patient and the length of time between doses. The delivered doses will be higher than with original eculizumab but not as much would be needed as previously because the interval between doses will be 8 weeks.  56 trialists have been recruited from 41 locations.

Recruitment to the children’s trial is still taking place and 16 candidates are being sought. As there will be 4 weight bands to determine dosage it is planned to have 4 patients for each band . The same dose interval of 8 weeks is being used.

These are the sites currently recruiting

United States.
Clinical Trial Site Recruiting
Hollywood, Florida, United States, 33021
 Georgia
Clinical Trial Site Recruiting
Atlanta, Georgia, United States, 30322
United States, Michigan
Clinical Trial Site Recruiting
Detroit, Michigan, United States, 48201
United States, Nebraska
Clinical Trial Site Recruiting
Omaha, Nebraska, United States, 68114-4113
Belgium
Clinical Trial Site Recruiting
Bruxelles, Belgium
Germany
Clinical Trial Site Recruiting
Heidelberg, Germany
Japan
Clinical Trial Site Recruiting
Fuchū, Japan
Korea, Republic of
Clinical Trial Site Recruiting
Jeju, Korea, Republic of
Clinical Trial Site Recruiting
Seoul, Korea, Republic of
Clinical Trial Site Recruiting
Yangsan, Korea, Republic of
Spain
Clinical Trial Site Recruiting
Barcelona, Spain

Click on the following links to find out more about what the trial is about , including the cities in which the adult trialists have been recruited.

Children ‘ s Trial

Adults’ Trial 

 

It is hopeful that this version will be as clinically effective as the original eculizumab which has transformed the lives of so many that have benefitted from it.

The treatment burden will be reduced too , just 6 infusion per year instead of 26 something to be welcomed.

But perhaps even more good may come , all things being equal , from the roughly 33% or more  reduction in the amount drug used reducing the cost of treatment and making it more affordable and sustainable for those in counties which deny or cap access because of affordability. Wouldn’t it be good if at least 50% more patients could access it when needed for as long as it is needed?

On the other hand the manufacturer may just increase the vial price by 50%.

That will be an acid test too.